Trials / Not Yet Recruiting
Not Yet RecruitingNCT05628610
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | 200mg d1, Q3W |
| RADIATION | Radiation | Radiotherapy dose: 5,000 c G y / 30f |
| DRUG | Paclitaxel | Paclitaxel: 150mg / m2 ,d1, q3w |
| DRUG | Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs | cisplatin, carboplatin, naidaplatin and other platinum drugs |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2026-09-30
- Completion
- 2027-09-30
- First posted
- 2022-11-28
- Last updated
- 2024-08-13
Source: ClinicalTrials.gov record NCT05628610. Inclusion in this directory is not an endorsement.